The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - GATEKEEPER Pharmaceuticals; Loxo
Consulting or Advisory Role - Araxes Pharma; ARIAD/Takeda; AstraZeneca; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Ignyta; Lilly; Loxo; Merrimack; Mirati Therapeutics; Novartis; Pfizer; Roche; SFJ Pharmaceuticals Group; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - Dana Farber Cancer Institute and LabCorp
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
 
Pasi A. Janne
No Relationships to Disclose
 
Joel W. Neal
Consulting or Advisory Role - ARIAD/Takeda; AstraZeneca; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Loxo
Research Funding - ARIAD/Takeda (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst)
 
D. Ross Camidge
Honoraria - AstraZeneca; bio-thera; Daiichi Sankyo; G1 therapeutics; Genoptix; Hansoh; Ignyta; Lycera; Mersana; Revolution Medicines; Roche; takeda
Research Funding - Takeda
 
Alexander I. Spira
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Zofia Piotrowska
Consulting or Advisory Role - AbbVie; ARIAD; AstraZeneca; Guardant Health; Novartis; Spectrum Pharmaceuticals; Takeda
Research Funding - ARIAD/Takeda; AstraZeneca; Guardant Health; Novartis; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - ARIAD/Takeda; AstraZeneca
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; Incyte; Janssen; Lilly; Merck; Tesaro; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
Daniel Botelho Costa
Honoraria - Pfizer; Takeda/Millennium
Consulting or Advisory Role - AstraZeneca; Takeda/Millennium
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Takeda/Millennium (Inst)
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Imedex; Lilly; MedImmune; Novartis; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck (Inst); Millennium; Polaris; Seagen
Patents, Royalties, Other Intellectual Property - UptoDate
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Takeda Science Foundation
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer; Takeda
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; Genentech/Roche; Lilly; Loxo; Pfizer; Takeda
Research Funding - BeyondSpring Pharmaceuticals
 
Viola Weijia Zhu
Stock and Other Ownership Interests - TP Therapeutics (I)
Honoraria - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda
Consulting or Advisory Role - TP Therapeutics
Speakers' Bureau - AstraZeneca; Roche/Foundation Medicine; Roche/Genentech; Takeda
 
Howard West
Honoraria - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Merck; Pfizer; PharmaMar; Spectrum Pharmaceuticals; Takeda
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Merck; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - ARIAD; AstraZeneca/MedImmune; Genentech/Roche; Lilly; Takeda
 
Sylvie Vincent
Employment - Takeda
 
Jian Zhu
Employment - Takeda
 
Shuanglian Li
Employment - Takeda
 
Gregory J. Riely
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme